Isolated Kidney Perfusion with TNF-α in Tumour-Bearing Rats
Author Information
Author(s): A H van der Veen, A L B Seynhaeve, J Breurs, P T G A Nooijen, R L Marquet, A M M Eggermont
Primary Institution: Department of Surgery, University Hospital Rotterdam Dijkzigt, Daniel den Hoed Cancer Centre, Rotterdam, The Netherlands
Hypothesis
Can isolated kidney perfusion with TNF-α lead to significant anti-tumour effects in solid organ tumours?
Conclusion
Isolated kidney perfusion with TNF-α did not result in a significant anti-tumour response in the studied tumour models.
Supporting Evidence
- The maximal tolerated dose of TNF-α was found to be only 1 μg.
- Higher doses of TNF-α caused renal failure and severe side effects.
- In vitro studies showed no synergistic effect of TNF-α and melphalan on certain cancer cells.
Takeaway
The study tested a treatment using a substance called TNF-α to see if it could help fight cancer in the kidneys, but it didn't work as hoped.
Methodology
The study involved in vivo isolated kidney perfusion models to assess the effects of TNF-α on tumour response.
Limitations
The study did not achieve the minimal threshold concentration of TNF-α needed for anti-tumour effects.
Participant Demographics
Tumour-bearing rats were used in the study.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website